March 10, 2022Open Access

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Key Points

Key points are not available for this paper at this time.

Abstract

Three times more patients were estimated to be alive at 3 years when treated with durvalumab plus EP versus EP, with the majority still receiving durvalumab at data cut-off, further establishing durvalumab plus EP as first-line standard of care for ES-SCLC.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Paz‐Ares et al. (Thu,) studied this question.

synapsesocial.com/papers/69d832dbf4e559c61eae2bbf https://doi.org/https://doi.org/10.1016/j.esmoop.2022.100408

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN2020 · 33 citations
2Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?2015 · 236 citations
3MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN2021 · 17 citations
4First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer2018 · 3,507 citations
5PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN2019 · 52 citations

Bookmark

View Full Paper